BiotechTube

Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + Oxaliplatin

Phase 2Recruiting
1 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma

Conditions

Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

Trial Timeline

Dec 13, 2024 → Oct 1, 2030

NCT ID
NCT06628310

About Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + Oxaliplatin

Telisotuzumab Adizutecan + Budigalimab + Fluorouracil + Leucovorin + Oxaliplatin is a phase 2 stage product being developed by AbbVie for Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06628310. Target conditions include Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma.

What happened to similar drugs?

5 of 20 similar drugs in Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma were approved

Approved (5) Terminated (1) Active (14)
✅letrozoleJiangsu Hengrui MedicineApproved
✅FulvestrantAstraZenecaApproved
✅PazopanibNovartisApproved
✅LetrozoleNovartisApproved
✅Trastuzumab emtansineRocheApproved
🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
🔄Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06628310Phase 2Recruiting

Competing Products

20 competing products in Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
27
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
35
NBTXR3NanobiotixPhase 1/2
33
Tadalafil + GemcitabineEli LillyPhase 1
29
SPYK04Chugai PharmaceuticalPhase 1
33
LUNA18 + CetuximabChugai PharmaceuticalPhase 1
21
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3
40
Trastuzumab Deruxtecan + Cisplatin + Carboplatin + Pembrolizumab + PemetrexedDaiichi SankyoPhase 3
44
T-DXd + Durvalumab + Cisplatin + Carboplatin + Pemetrexed + Volrustomig + RilvegostomigDaiichi SankyoPhase 1
36
ASP2998 + Pembrolizumab + Enfortumab Vedotin + CarboplatinAstellas PharmaPhase 1/2
39
zolbetuximabAstellas PharmaPre-clinical
30
enfortumab vedotin + pembrolizumabAstellas PharmaPhase 2
39
zolbetuximab + placebo + oxaliplatin + folinic acid + fluorouracilAstellas PharmaPhase 3
44
enfortumab vedotin (EV)Astellas PharmaPre-clinical
26
zolbetuximabAstellas PharmaPre-clinical
33
zolbetuximab + oxaliplatin + capecitabine + placeboAstellas PharmaPhase 3
44
ASP3082Astellas PharmaPhase 2
42
zolbetuximab + Pembrolizumab + Capecitabine + Oxaliplatin + Folinic acid (leucovorin or local equivalent) + 5-fluorouracil (5-FU) + PlaceboAstellas PharmaPhase 3
47
ASP1948Astellas PharmaPhase 1
29
Camrelizumab + SOX (oxaliplatin + Teggio) /XELOX (oxaliplatin + capecitabine )Sun PharmaceuticalPhase 2
31